Marizyme (MRZM) Stock Analysis & Winston Score

Marizyme is a small biotechnology company focused on developing medical treatments that are not yet approved or widely available. Its main work centers on enzyme-based therapies, including a drug candidate called Krillase, which is being studied to help dissolve blood clots and treat certain heart and vascular conditions. The company targets hospitals and patients dealing with serious cardiovascular and surgical complications. Marizyme does not yet generate meaningful revenue from product sales, which explains its deeply negative operating margin. It is a pre-commercial stage company based in the United States, spending most of its cash on research and clinical development rather than selling finished products. The biggest risk the company faces is the long and expensive process of getting its drug candidates approved by the FDA — without approval, it cannot sell its therapies, and it will likely need to raise additional money to keep operating.